Cempra is a clinical-stage pharmaceutical company engaged in developing antibiotics to meet critical needs in treating bacterial infectious diseases. The company’s two lead product candidates, solithromycin and CEM-102, are currently in advanced clinical development – both aimed at addressing the need for new treatments targeting drug-resistant bacterial infections. Cempra additionally plans to use its series of proprietary lead compounds from its novel macrolide library to treat chronic inflammatory diseases, endocrine diseases, gastric motility disorders and others. For more information, visit the company’s Web site at www.cempra.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: